ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 33 of 8648 for:    "Breast Neoplasms"

Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00194740
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : December 6, 2007
Sponsor:
Collaborator:
Aventis Pharmaceuticals
Information provided by:
University of Washington

Brief Summary:
The two drugs used to treat metastatic breast cancer in this study may perform better when used together than when used separately. The use of another drug that prevents the most common side effect of the two-drug combination permits the delivery of both agents at closer to the "full" dose for either when used alone. We hypothesize that the two-drug combination used with G-CSF support will be more effective and less toxic than other standard regimens for the treatment of metastatic breast cancer.

Condition or disease Intervention/treatment Phase
Breast Neoplasm Drug: Docetaxel Drug: Vinorelbine Drug: Filgrastim Phase 2

Detailed Description:
Preclinical data suggest that there may be synergy between vinorelbine and paclitaxel when the two drugs are used in combination such that the effect of the two together may be better than either alone. Clinical data suggest that the use of concurrent G-CSF with paclitaxel and vinorelbine permits the delivery of both agents at approximately 70% of the "full" dose for either, used alone without G-CSF support, with myelosuppression as the usual dose-limiting toxicity and no unusual or unexpected complications. Encouragingly, 8/20 (40%) patients had objective responses, with three complete remissions (15%) in this program of third-line therapy. Therefore, we now propose to combine docetaxel at about 70% of "full" dose with vinorelbine at 27.5 mg/m2, the "phase II" dose defined in the previous trial. Docetaxel will be given on day 1 followed by vinorelbine on days 8 and 15, with G-CSF to be administered on all days except that of docetaxel administration. The cycle is to be repeated every three weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Taxotere Plus Weekly Navelbine and G-CSF: A Phase II Study in Stage IV Breast Cancer
Study Start Date : November 1997
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: 1 Drug: Docetaxel
60 mg/m2, IV, day 1 of each 21 day cycle
Other Name: Taxotere

Drug: Vinorelbine
27.5 mg/m2, IV, days 8 & 15 of each 21 day cycle
Other Name: Navelbine

Drug: Filgrastim
5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
Other Name: G-CSF, Neupogen




Primary Outcome Measures :
  1. Response to treatment [ Time Frame: Until disease progression ]
  2. Toxicity of treatment [ Time Frame: Until completion of treatment ]

Secondary Outcome Measures :
  1. Time to progression [ Time Frame: Until disease progression occurs ]
  2. Over all survival [ Time Frame: Until study is closed ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have stage IV, microscopically-confirmed carcinoma of the breast with histologic slides and/or blocks available for review.
  • Patients must have relapse or progression while receiving, or within 12 months of having received, anthracycline-containing (doxorubicin or mitoxantrone) regimen as either adjuvant treatment or therapy for advanced breast cancer. Prior Taxol by 3- or 24-hour infusion is permitted. Patients who have received a maximum dose of anthracycline (greater than 450 mg/m2) are also eligible.
  • Patients must have measurable (bidimensionally) or evaluable disease.
  • Patients must be 18 or more years of age.
  • Patients must have a Karnofsky Performance Status greater than or equal to 70% at screen and on the first day of treatment.
  • Patients must have a life expectancy of more than 16 weeks.
  • Prior irradiation is permitted, provided that prior irradiation does not exceed 25% of the estimated bone marrow volume and provided that measurable/evaluable disease exists outside the radiation field OR there must be histologic proof of progressive disease within a radiation field.
  • Informed consent must be obtained prior to registration.
  • Patients must be more than 2 weeks from prior surgery; more than 3 weeks from radiation therapy to the pelvis, spine or long bones; more than 3 weeks from prior chemotherapy (more than 6 weeks for mitomycin C or nitrosureas), or more than 2 weeks from prior hormonal therapy.
  • All patients must have appropriate central venous access.

Exclusion Criteria:

Patients are excludes if their:

  • Granulocyte count is less than 1,500/mm3.
  • Platelet count is less than 100,000/mm3.
  • Hemoglobin is less than 9 gm/dl.
  • Creatinine is greater than 2.0 mg/dl.
  • Total bilirubin is greater than ULN (institutional upper limit of normal)..
  • SGOT (AST) and/or SGPT (ALT) is greater than 1.5 x ULN concomitant with alkaline phosphatase greater than 2.5 x ULN.

Patients are excluded if they are:

  • In visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases.
  • Medically unstable.
  • Pregnant or lactating.

Patients are excluded if they have:

  • Uncontrolled CNS disease.
  • Pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer.
  • Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol.
  • Prior therapy with Navelbine.
  • Sensitivity to E. Coli-derived proteins.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00194740


Locations
United States, Washington
University of Washington/Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109-1023
Sponsors and Collaborators
University of Washington
Aventis Pharmaceuticals
Investigators
Principal Investigator: Julie R. Gralow, M.D. University of Washington

Responsible Party: Julie Gralow, M.D., University of Washington
ClinicalTrials.gov Identifier: NCT00194740     History of Changes
Other Study ID Numbers: 97-5372-A
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: December 6, 2007
Last Verified: December 2007

Keywords provided by University of Washington:
Breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Vinorelbine
Docetaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action